TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
Brief Summary: Part 1 (Phase 1): safety and tolerability of bevacizumab-Niraparib combination Part 2 (Randomized Phase 2): to compare Progression-Free Survival (PFS)

PARP inhibitors are active as monotherapy to treat patients with recurrent ovarian cancer; the strongest activity being observed in the platinum sensitive, gBRCAmut subgroup as well as in gBRCAwt, HRD population but also in HRD negative disease.

In the same population there is level one evidence that bevacizumab is beneficial. And a phase two randomized study has indicated that combination of a PARP inhibitor with anti-angiogenic drug is superior to PARP inhibitor alone.

The question is:

Is niraparib combined with bevacizumab superior to niraparib? The comparison of tolerability and efficacy of niraparib-bevacizumab combination against niraparib.


Options:
A: Intervention Type: DRUG; Name: PARP Inhibitors; Assigned to Arm(s): N/A
B: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment B; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: Treatment C; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): Treatment A, Treatment B, Treatment C
C: Arm Label: Arm 1 (ceralasertib+olaparib); Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Ceralasertib | Arm Label: Arm 2 (olaparib monotherapy); Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Arm 3 (placebo); Type: EXPERIMENTAL; Interventions: Drug: Placebo to match olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib), Arm 2 (olaparib monotherapy) | Intervention Type: DRUG; Name: Ceralasertib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib) | Intervention Type: DRUG; Name: Placebo to match olaparib; Assigned to Arm(s): Arm 3 (placebo)
D: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Commitment and Motivation in a Brief DBT Intervention for Self Harm
Brief Summary: Research suggests that individuals with Borderline Personality Disorder (BPD) experience low motivation for change (Skodal, Buckley, \& Charles, 1983). Dialectical Behavior Therapy (DBT; Linehan, 1993) includes commitment strategies that are designed to improve motivation. No studies have examined the effectiveness of these strategies. The proposed study will evaluate the efficacy of a brief DBT intervention consisting of commitment strategies plus skills training for people who self-harm. Participants will be randomly assigned to either a single orientation session of (1) commitment strategies plus psychoeducation or (2) psychoeducation. Immediately following their orientation session, all participants will be enrolled in a 90 minute group skills training session. Primary outcomes include autonomous motivation and frequency of self harm behaviours. Assessments will be conducted at six time points: baseline, after the initial orientation session, after the skills training group session, and at one week, one month, and three month follow-up


Options:
A: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
B: Arm Label: TAU w/ mobile app + volunteer support; Type: EXPERIMENTAL; Interventions: Behavioral: Volunteer support, Other: Mobile app | Arm Label: TAU w/ mobile app engagement; Type: EXPERIMENTAL; Interventions: Other: Mobile app | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Volunteer support; Assigned to Arm(s): TAU w/ mobile app + volunteer support | Intervention Type: OTHER; Name: Mobile app; Assigned to Arm(s): TAU w/ mobile app + volunteer support, TAU w/ mobile app engagement
C: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
D: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Commitment and Motivation in a Brief DBT Intervention for Self Harm
Brief Summary: Research suggests that individuals with Borderline Personality Disorder (BPD) experience low motivation for change (Skodal, Buckley, \& Charles, 1983). Dialectical Behavior Therapy (DBT; Linehan, 1993) includes commitment strategies that are designed to improve motivation. No studies have examined the effectiveness of these strategies. The proposed study will evaluate the efficacy of a brief DBT intervention consisting of commitment strategies plus skills training for people who self-harm. Participants will be randomly assigned to either a single orientation session of (1) commitment strategies plus psychoeducation or (2) psychoeducation. Immediately following their orientation session, all participants will be enrolled in a 90 minute group skills training session. Primary outcomes include autonomous motivation and frequency of self harm behaviours. Assessments will be conducted at six time points: baseline, after the initial orientation session, after the skills training group session, and at one week, one month, and three month follow-up


Options:
A: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
B: Arm Label: Computer Assisted CIFFTA; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Assisted CIFFTA | Arm Label: Behavioral: Traditional face-to-face treatment-no technology; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Traditional face-to-face treatment-no technology | Intervention Type: BEHAVIORAL; Name: Computer Assisted CIFFTA; Assigned to Arm(s): Computer Assisted CIFFTA | Intervention Type: BEHAVIORAL; Name: Behavioral: Traditional face-to-face treatment-no technology; Assigned to Arm(s): Behavioral: Traditional face-to-face treatment-no technology
C: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Inidividual and Group Supportive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual and Group Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Individual and Group Supportive Therapy; Assigned to Arm(s): Inidividual and Group Supportive Therapy
D: Arm Label: Positive Psychology; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychology | Arm Label: Organizational Skills; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Positive Psychology; Assigned to Arm(s): Positive Psychology | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Organizational Skills

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Commitment and Motivation in a Brief DBT Intervention for Self Harm
Brief Summary: Research suggests that individuals with Borderline Personality Disorder (BPD) experience low motivation for change (Skodal, Buckley, \& Charles, 1983). Dialectical Behavior Therapy (DBT; Linehan, 1993) includes commitment strategies that are designed to improve motivation. No studies have examined the effectiveness of these strategies. The proposed study will evaluate the efficacy of a brief DBT intervention consisting of commitment strategies plus skills training for people who self-harm. Participants will be randomly assigned to either a single orientation session of (1) commitment strategies plus psychoeducation or (2) psychoeducation. Immediately following their orientation session, all participants will be enrolled in a 90 minute group skills training session. Primary outcomes include autonomous motivation and frequency of self harm behaviours. Assessments will be conducted at six time points: baseline, after the initial orientation session, after the skills training group session, and at one week, one month, and three month follow-up


Options:
A: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy
B: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
C: Arm Label: Cognitive behavioral therapy (CBT) + standard care; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: Standard care alone | Arm Label: Standard care alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care alone | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care | Intervention Type: BEHAVIORAL; Name: Standard care alone; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care, Standard care alone
D: Arm Label: SAFE VET; Type: N/A; Interventions: Behavioral: SAFE VET | Arm Label: E-CARE; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SAFE VET; Assigned to Arm(s): SAFE VET

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Brief Summary: This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first generation somatostatin analogues. The study will enroll inadequately controlled patients by high doses (maximal approved) of first-generation somatostatin analogues given for at least 3 months. Patients will receive pasireotide LAR 40 mg or 60 mg during the 36 week core study phase. Patients who have completed all visits of core phase and have completed all the assessments at the core phase completion visit can move into the 32-week extension phase. Patients can continue with study treatment until pasireotide LAR is commercially available and reimbursed in their respective country or until the end of the extension phase whichever occurs first.


Options:
A: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide LAR | Intervention Type: DRUG; Name: Pasireotide LAR; Assigned to Arm(s): Pasireotide LAR
B: Arm Label: CAM2029 10 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 10 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Intervention Type: DRUG; Name: octreotide FluidCrystal® injection depot; Assigned to Arm(s): CAM2029 10 mg (Acromegaly), CAM2029 10 mg (NET), CAM2029 20 mg (Acromegaly), CAM2029 20 mg (NET)
C: Arm Label: octreotide; Type: EXPERIMENTAL; Interventions: Drug: Octreotide | Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Direct surgery for acromegaly | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): octreotide | Intervention Type: PROCEDURE; Name: Direct surgery for acromegaly; Assigned to Arm(s): standard surgery
D: Arm Label: Lanreotide autogel 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide autogel 120 mg | Intervention Type: DRUG; Name: Lanreotide autogel 120 mg; Assigned to Arm(s): Lanreotide autogel 120 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)
Brief Summary: What is heart failure with normal ejection fraction? The heart contracts (pumps) and relaxes with each heartbeat. In some people with heart failure, the heart contracts normally but there is reduced relaxation of the heart. As a result, people notice a feeling of breathlessness, ankle swelling and fatigue especially on exertion.

The investigators feel that patients with reduced or impaired relaxation of the heart have less heart filling time and poor energy utilisation during exercise. Therefore, the investigators are conducting a study to more thoroughly understand the disease condition by giving a drug called ivabradine to reduce the heart rate and hence to increase the heart filling time in these patients.


Options:
A: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
B: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ivabradine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivabradine | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Active arm, Placebo arm
C: Arm Label: Ivabradine; Type: EXPERIMENTAL; Interventions: Drug: Ivabradine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Ivabradine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I
Brief Summary: This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in 2 centres in Sweden to assess the effect of Omega-3 carboxylic acids and fenofibrate on liver fat measured with magnetic resonance imaging (MRI) in patients with over-weight and hypertriglyceridemia.


Options:
A: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish oil, Placebo
B: Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Unsupervised exercise training | Arm Label: lifestyle counseling and exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised exercise training | Intervention Type: BEHAVIORAL; Name: Unsupervised exercise training; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Supervised exercise training; Assigned to Arm(s): lifestyle counseling and exercise
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Omega-3 carboxylic acids 4g / day; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 carboxylic acid | Arm Label: Fenofibrate 200mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fenofibrate 200mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Omega-3 carboxylic acid; Assigned to Arm(s): Omega-3 carboxylic acids 4g / day | Intervention Type: DRUG; Name: Fenofibrate 200mg; Assigned to Arm(s): Fenofibrate 200mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism
Brief Summary: This study is looking at the safety and effectiveness of treating Patients diagnosed with a low-risk Pulmonary Embolism (PE) in an outpatient setting instead of the standard, in-patient hospitalization. Patients have several medical tests done during their Emergency Department visit. Based on those tests, those who are determined to have a low-risk PE are eligible to participate in the study. Those choosing to participate are discharged after 12 hours of medical observation. Patients who choose to participate are followed up by telephone approximately 90 days later.


Options:
A: Arm Label: HESTIA group; Type: OTHER; Interventions: Other: HESTIA | Arm Label: sPESI group; Type: OTHER; Interventions: Other: sPESI | Intervention Type: OTHER; Name: HESTIA; Assigned to Arm(s): HESTIA group | Intervention Type: OTHER; Name: sPESI; Assigned to Arm(s): sPESI group
B: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
C: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A
D: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism
Brief Summary: This study is looking at the safety and effectiveness of treating Patients diagnosed with a low-risk Pulmonary Embolism (PE) in an outpatient setting instead of the standard, in-patient hospitalization. Patients have several medical tests done during their Emergency Department visit. Based on those tests, those who are determined to have a low-risk PE are eligible to participate in the study. Those choosing to participate are discharged after 12 hours of medical observation. Patients who choose to participate are followed up by telephone approximately 90 days later.


Options:
A: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment
B: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
C: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
D: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The aim of the current study is to evaluate the effects of diets with three levels of dietary fat on weight change and related cardiometabolic risk factors in a 6-month randomized controlled-feeding trial.


Options:
A: Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie
B: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
C: Arm Label: low-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-fat diet | Arm Label: moderate-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: moderate-fat diet | Arm Label: high-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: high-fat diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate-fat diet; Assigned to Arm(s): moderate-fat diet | Intervention Type: BEHAVIORAL; Name: high-fat diet; Assigned to Arm(s): high-fat diet
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2

Answer: C